Welcome to our dedicated page for Biophytis Sa SEC filings (Ticker: BPTSY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a 200-page biotech filing loaded with clinical endpoints, trial acronyms and licensing clauses is daunting. Biophytis SA’s disclosures are especially dense because every 10-K and 10-Q tracks the evolving BIO101 pipeline, cash runway and global co-development deals. If you have ever wondered, “How do I find Biophytis insider trading Form 4 transactions before a trial milestone?” this page solves that problem.
Stock Titan’s AI scans each Biophytis SEC submission the moment it hits EDGAR, then delivers plain-English summaries, red-flags critical sections and links you straight to the numbers that matter. Use it to grasp a Biophytis quarterly earnings report 10-Q filing without wading through accounting footnotes, or to see Form 4 insider transactions in real-time when executives adjust their holdings. Need the BIO101 clinical update buried in an 8-K? Our engine highlights it and explains why the event is material.
Common investor tasks become effortless:
- Compare R&D spend across quarters with one-click 10-Q trend charts.
- Set alerts for Biophytis executive stock transactions Form 4 and receive context on historical trading patterns.
- Download an annual report 10-K simplified section that maps trial phases to projected cash requirements.
- Review the latest proxy statement executive compensation tables side-by-side with peer biotech benchmarks.
BlackRock Portfolio Management LLC filed a Schedule 13G reporting beneficial ownership of 1,215,469 shares (5.2%) of Biophytis SA common stock. The filing indicates sole voting power over 1,215,469 shares and sole dispositive power over 1,215,469 shares, with no shared voting or dispositive power.
The event date is 09/30/2025. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The CUSIP is F1022R155. Item 6 notes that Kreos Capital VI (Expert Fund) LP has an interest in more than five percent of the company’s common stock.
Biophytis S.A. reported that it issued a press release announcing a partnership with a consortium of investors, including RONGHUI RENHE Life Technology, to finance and launch the first ever Phase-3 trial in sarcopenia. The announcement was furnished on a Form 6-K and the press release is provided as Exhibit 99.1.
FAQ
What is the current stock price of Biophytis Sa (BPTSY)?
What is the market cap of Biophytis Sa (BPTSY)?
